Posted: May 11, 2025 at 2:46 am
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025.
Originally posted here:
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
Posted: May 11, 2025 at 2:46 am
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
Read more from the original source:
Oculis Publishes Invitation to the Annual General Meeting
Posted: May 11, 2025 at 2:46 am
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
Read this article:
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
Posted: May 11, 2025 at 2:46 am
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Continued here:
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
Posted: May 11, 2025 at 2:45 am
New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal fluid administration in non-human primates
Read this article:
Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases
Posted: May 11, 2025 at 2:45 am
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension
See the original post here:
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Posted: May 11, 2025 at 2:45 am
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response
See the rest here:
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Posted: May 11, 2025 at 2:45 am
The best probiotics for bloating and gas include strains like Lactobacillus rhamnosus GG, Lactobacillus acidophilus, and Bifidobacterium lactis, which help balance gut bacteria, improve digestion, and reduce bloating, flatulence, and constipation naturally and effectively. The best probiotics for bloating and gas include strains like Lactobacillus rhamnosus GG, Lactobacillus acidophilus, and Bifidobacterium lactis, which help balance gut bacteria, improve digestion, and reduce bloating, flatulence, and constipation naturally and effectively.
Read more from the original source:
Best Probiotic for Bloating, Gas, and Constipation: Top Probiotic Supplements for Gut Health to Reduce Bloating, Indigestion & Flatulence...
